Review and Preview
Review and Preview
Chronic Pancreatitis II: Collaborative Care
Interdisciplinary Care: The Health Care Team-I
Interdisciplinary Care: The Health Care Team-II
Formation of Complex Ions
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Feb 16, 2026

Simulation of a Scaled Assembly Process with Collaboration of a Robotic Arm and Monitoring through a Vision System for Quality Control
Published on: August 29, 2025
Maria Stratton1, Philip Grgurich2, Kurt Heim3
11 North Shore Medical Center Salem Hospital, Salem, MA, USA.
This study compared two methods for reversing the effects of warfarin: prothrombin complex concentrate (PCC4) and fresh frozen plasma (FFP). Researchers looked at how quickly each method could be administered and how well they corrected blood clotting levels. They found that PCC4 was administered faster and corrected clotting levels more often than FFP. Both methods had similar safety profiles. The study suggests that using PCC4 with a collaborative pharmacy-based process could be more effective in urgent situations.
Area of Science:
Background:
Current evidence shows that vitamin K antagonist reversal requires either prothrombin complex concentrate or fresh frozen plasma. Prior research has shown that FFP requires longer preparation times and may not correct INR as quickly. However, no prior work had resolved whether a collaborative pharmacy-based dispensing model could improve PCC4 use. This gap motivated a study to compare reversal processes. Existing knowledge lacked data on real-world effectiveness of PCC4 in urgent settings. No prior work had resolved the impact of interdisciplinary review on administration speed. This paper contributes by analyzing a new workflow. The study's design addresses a practical gap in emergency anticoagulation reversal. It builds on prior work but introduces a novel pharmacy integration.
Purpose Of The Study:
The aim was to evaluate a new collaborative process for PCC4 administration in warfarin reversal. The specific problem was the need for faster and more effective reversal in urgent clinical scenarios. This study sought to compare PCC4 and FFP in a real-world setting. The motivation came from observed delays in FFP preparation and administration. The study aimed to assess whether interdisciplinary review improved outcomes. It also sought to measure INR correction rates and adverse event frequencies. The goal was to determine if PCC4 could be safely and effectively integrated into clinical practice. The study focused on time metrics and safety outcomes.
Main Methods:
The study used a retrospective before-and-after cohort design at a single center. Researchers analyzed 98 patients requiring urgent warfarin reversal. Data collection included timing metrics and INR measurements. The primary endpoint was time from order to administration. Secondary endpoints included infusion duration and INR correction rates. Patients were divided into two groups: FFP and PCC4 recipients. Adverse events were tracked for both groups. Statistical analysis compared median times and correction rates between groups.
Main Results:
Median administration time for PCC4 was 44 minutes versus 69 minutes for FFP (P = 0.015). Infusion time for PCC4 was 54 minutes compared to 151 minutes for FFP (P < 0.0001). INR correction to ≤1.4 occurred in 72% of PCC4 patients versus 28% of FFP patients (P < 0.0001). Adverse events occurred in 4% of both groups. These findings suggest faster PCC4 administration and better INR correction. The study also found similar safety profiles between the two agents. These results were consistent across the study period. The data support the effectiveness of the new dispensing model.
Conclusions:
The authors propose that PCC4, when used with collaborative review and pharmacy dispensing, offers faster administration. They suggest that this process improves INR correction rates compared to FFP. The study found similar adverse event rates between the two agents. These findings support the use of PCC4 in urgent reversal scenarios. The authors state that the new workflow is feasible in clinical practice. They suggest that the model could improve emergency anticoagulation management. The study does not claim that PCC4 is superior in all aspects. The authors emphasize the importance of interdisciplinary collaboration.
The main outcome is faster administration and higher INR correction rates compared to FFP.
The model involves collaborative prospective review and pharmacy preparation of PCC4.
Shorter infusion times improve clinical outcomes in urgent reversal scenarios.
INR correction to ≤1.4 indicates successful reversal of anticoagulation.
Adverse events occurred in 4% of patients in both groups.
The authors suggest that PCC4 with collaborative review improves reversal efficiency.